1-2 of 2
Emily Burton
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A phase I study of the combination of ruxolitinib and the ERK1/2 inhibitor ulixertinib in previously treated myelofibrosis patients.

Free
Chi-Joan How, Gabriela Hobbs, Aaron Gerds, Andriy Derkach, Emily Burton, Aurora Duran, Katherine Kan, Michael Mauro, Brian Chernak, Tamanna Haque, Raajit Rampal
Journal: Blood
Blood (2025) 146 (Supplement 1): 5606.
https://doi.org/10.1182/blood-2025-5606
Published: 2025
Journal Articles

The combination of ruxolitinib and the CDK4/6 inhibitor abemaciclib demonstrates safety and efficacy in previously treated myelofibrosis patients: Results of A phase I study

Free
Jan Philipp Bewersdorf, Andriy Derkach, Amer Zeidan, Emily Burton, Katherine Kan, Marissa Giuliani, Jeetayu Biswas, Michael Mauro, Brian Chernak, Tamanna Haque, Nikolai Podoltsev, Ross Levine, Prithviraj Bose, Raajit Rampal
Journal: Blood
Blood (2025) 146 (Supplement 1): 3814.
https://doi.org/10.1182/blood-2025-3814
Published: 2025